MiR-31 as a predictive biomarker of cetuximab efficacy in metastatic colorectal cancer patients: systematic review - PubMed
6 hours ago
- #metastatic colorectal cancer
- #predictive biomarker
- #miR-31
- Low miR-31-3p expression is consistently associated with improved cetuximab efficacy in metastatic colorectal cancer (mCRC), including better overall survival, progression-free survival, and overall response rates.
- Elevated miR-31 expression is linked to shorter progression-free survival, indicating potential resistance to cetuximab.
- MiR-31-3p does not predict anti-EGFR efficacy in right-sided tumors, suggesting tumor sidedness may influence its predictive value.
- Current biomarkers like RAS and BRAF mutations are insufficient for fully predicting cetuximab response, highlighting the need for additional markers.
- Prospective validation studies with standardized assays are required before clinical implementation of miR-31-3p as a biomarker.